36 Views | 25 Downloads
Correspondence: Shannon L. Meeks, smeeks@emory.edu
Author contributions: GB designed and performed the experiments, analyzed the data, and wrote the article. JI, CC, EY, WB, SG, and PL conducted the experiments and acquired the data. PL and SM analyzed the data and edited the article. All authors contributed to the article and approved the submitted version.
Acknowledgements: We would like to acknowledge and thank Curtis Henry, PhD, at Emory University for his helpful input and discussion of this article. Figures 5A, 7A, 8A, D were adapted from “Immunogenicity Assay” by BioRender.com (2022).
Competing interests: GB has received honoraria for advisory board participation from Bayer, Genentech, Octapharma, Kedrion, and Sanofi. PL is an inventor on patents owned by Emory University claiming compositions of matter that include modified FVIII proteins with reduced reactivity with anti-FVIII antibodies. SM has received honoraria for participation in advisory boards from Sanofi, Bayer, Novo Nordisk, CSL Behring, Genentech, HEMA Biologics, Takeda, Spark, Pfizer, Biomarin, and TeraImmune and has received research grants from Octapharma and Genentech. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
This research was supported by the Atlanta Pediatric Scholars Program K12 HD072245 (GB), 2016 Hemostasis and Thrombosis Research Society/Novo Nordisk Mentored Research Award in Hemophilia and Rare Bleeding Disorders from the Hemostasis and Thrombosis Research Society supported by an educational grant from Novo Nordisk Inc. (GB), the Hemophilia of Georgia Clinical Scientist Development Award (GB), NHLBI grant K99HL150595 (GB), NHLBI grant U54HL141981 (SM and PL), and Hemophilia of Georgia, Inc. (SM and PL).
© 2023 Batsuli, Ito, York, Cox, Baldwin, Gill, Lollar and Meeks